Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Pancreatic Cancer

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Pancreatic Ductal Adenocarcinoma (133)

Pancreatic Adenocarcinoma (81)

Pancreatic Ductal Adenocarcinoma (133)

Pancreatic Adenocarcinoma (81)

›

BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Pancreatic Cancer	BRCA1 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval 5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive : A1	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval 5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive : A1
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
NRG1 fusion	Pancreatic Ductal Adenocarcinoma	NRG1 fusion	Pancreatic Ductal Adenocarcinoma	zenocutuzumab-zbco Sensitive: A1 - Approval zenocutuzumab-zbco Sensitive : A1	zenocutuzumab-zbco Sensitive: A1 - Approval zenocutuzumab-zbco Sensitive : A1
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
NTRK3 fusion	Pancreatic Adenocarcinoma	NTRK3 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Pancreatic Adenocarcinoma	NTRK2 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Pancreatic Adenocarcinoma	NTRK1 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2